The stock of Vascular Solutions, Inc. (NASDAQ:VASC) hit a new 52-week high and has $57.98 target or 7.00% above today’s $54.19 share price. The 9 months bullish chart indicates low risk for the $952.92 million company. The 1-year high was reported on Nov, 28 by Barchart.com. If the $57.98 price target is reached, the company will be worth $66.70M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 77,317 shares traded hands. Vascular Solutions, Inc. (NASDAQ:VASC) has risen 46.94% since April 25, 2016 and is uptrending. It has outperformed by 40.93% the S&P500.
Analysts await Vascular Solutions, Inc. (NASDAQ:VASC) to report earnings on January, 19. They expect $0.34 earnings per share, up 3.03% or $0.01 from last year’s $0.33 per share. VASC’s profit will be $5.98M for 39.85 P/E if the $0.34 EPS becomes a reality. After $0.31 actual earnings per share reported by Vascular Solutions, Inc. for the previous quarter, Wall Street now forecasts 9.68% EPS growth.
Vascular Solutions, Inc. (NASDAQ:VASC) Ratings Coverage
Out of 3 analysts covering Vascular Solutions (NASDAQ:VASC), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Vascular Solutions has been the topic of 3 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The rating was maintained by Piper Jaffray on Tuesday, August 11 with “Overweight”. The firm has “Buy” rating by Needham given on Thursday, October 6.
According to Zacks Investment Research, “Vascular Solutions Inc. manufactures, markets and sells the Vascular Solutions Duett sealing device, which enables cardiologists and radiologists to rapidly seal the puncture site following catheterization procedures such as angiography, angioplasty and stenting. Its product combines a simple balloon catheter delivery mechanism with a powerful, proprietary procoagulant. The company believes its product offers advantages over both manual compression and the three other FDA-approved devices used to seal the puncture site following the catheterization.”
Insitutional Activity: The institutional sentiment increased to 1.2 in 2016 Q2. Its up 0.01, from 1.19 in 2016Q1. The ratio increased, as 10 funds sold all Vascular Solutions, Inc. shares owned while 44 reduced positions. 15 funds bought stakes while 49 increased positions. They now own 14.00 million shares or 4.98% more from 13.33 million shares in 2016Q1.
The Texas-based Capstone Asset Mgmt Com has invested 0.01% in Vascular Solutions, Inc. (NASDAQ:VASC). Moreover, Ranger Invest Mngmt L P has 0.97% invested in Vascular Solutions, Inc. (NASDAQ:VASC) for 376,182 shares. Zurcher Kantonalbank (Zurich Cantonalbank), a Switzerland-based fund reported 1,023 shares. Deutsche National Bank Ag reported 29,363 shares or 0% of all its holdings. State Bank Of Montreal Can has 4,848 shares for 0% of their US portfolio. Envestnet Asset Mngmt Inc last reported 5,859 shares in the company. Northern Trust Corp reported 216,881 shares or 0% of all its holdings. Moreover, Waddell And Reed Fincl has 0.01% invested in Vascular Solutions, Inc. (NASDAQ:VASC) for 135,521 shares. Blackrock Group Incorporated Ltd, a United Kingdom-based fund reported 17,600 shares. Ladenburg Thalmann Service holds 900 shares or 0% of its portfolio. Gru last reported 0% of its portfolio in the stock. Morgan Stanley holds 0% of its portfolio in Vascular Solutions, Inc. (NASDAQ:VASC) for 6,281 shares. Renaissance Tech Ltd, a New York-based fund reported 442,700 shares. Menta Cap Limited Liability accumulated 7,991 shares or 0.05% of the stock. Credit Suisse Ag accumulated 0% or 18,561 shares.
Insider Transactions: Since July 27, 2016, the stock had 0 buys, and 2 insider sales for $2.27 million net activity. ROOT HOWARD sold $1.80 million worth of Vascular Solutions, Inc. (NASDAQ:VASC) on Wednesday, July 27. On Wednesday, July 27 the insider RUTSTEIN WILLIAM sold $463,109.
More news for Vascular Solutions, Inc. (NASDAQ:VASC) were recently published by: Globenewswire.com, which released: “Vascular Solutions Receives 510(k) Clearance for Fluentâ„¢ Inflation Device” on October 21, 2016. Globenewswire.com‘s article titled: “Vascular Solutions and Howard Root Found Not Guilty on All Charges in Short …” and published on February 26, 2016 is yet another important article.
VASC Company Profile
Vascular Solutions, Inc., incorporated on December 20, 1996, is a medical device firm focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. The Company’s products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Firm creates minimally invasive medical devices and then delivers these products and related services to physicians through its direct domestic sales force and its international distribution network.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.